For example, luminal bladder cancer cell lines were enriched for mutation and amplifications in FGFR3, while mutations in TP53 and deletions of CDKN2A were more evenly distributed throughout the cell lines examined, much as is the case with clinical disease. This evidence concerns the gene FGFR3 and urinary bladder cancer.